[go: up one dir, main page]

WO2024231774A1 - Produits pharmaceutiques contenant des chélateurs ayant une forte capacité de rétention des ions zn pour le traitement de symptômes et de maladies provoqués par des micro-organismes/maladies provoqués par des toxines ou des neurotoxines/cancer/plusieurs syndromes - Google Patents

Produits pharmaceutiques contenant des chélateurs ayant une forte capacité de rétention des ions zn pour le traitement de symptômes et de maladies provoqués par des micro-organismes/maladies provoqués par des toxines ou des neurotoxines/cancer/plusieurs syndromes Download PDF

Info

Publication number
WO2024231774A1
WO2024231774A1 PCT/IB2024/054083 IB2024054083W WO2024231774A1 WO 2024231774 A1 WO2024231774 A1 WO 2024231774A1 IB 2024054083 W IB2024054083 W IB 2024054083W WO 2024231774 A1 WO2024231774 A1 WO 2024231774A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
pharmaceuticals
symptoms
tissues
ions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2024/054083
Other languages
English (en)
Inventor
Cong Nhan Huynh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2024269697A priority Critical patent/AU2024269697A1/en
Publication of WO2024231774A1 publication Critical patent/WO2024231774A1/fr
Priority to IL324359A priority patent/IL324359A/en
Priority to MX2025013222A priority patent/MX2025013222A/es
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the invention belongs to the pharmaceutical field containing a chelating agent with the ability to retain [Zn ions/other heavy metal ions] to treat symptoms of diseases caused by pathogenic microorganisms and to prevent or treat diseases caused by pathogenic microorganisms/diseases caused by toxins and neurotoxins/diseases that weaken the immune system due to chronic diseases or due to the decline of polyamine derivatives in the elderly/ cancer / some other diseases / some syndromes / diseased tissues (such as infection tissues/ necrotic tissues/ tissues containing many toxins / benign tumors/cancerous tumors).
  • chelators with [Zn ions/other transition metal ions]-holding feature are agents that create a series of effects as outlined below to help the host body to recover quickly, so up to now, there are no pharmaceuticals containing chelators with [Zn ions/other transition metal ions] -holding feature are to prevent or to treat symptoms/diseases as mentioned above; and so far biology/medicine does not know when to introduce [agents that produce strong physical effects + chelators with [Zn ions/other transition metal ions] -holding feature] + without agent that creates the foam structure for diseased tissue/with agent that creates the foam structure for diseased tissue] (or with the addition of other therapeutic active ingredients, collectively referred to as chelator and other therapeutic active ingredients as therapeutic active ingredients) into diseased tissue (such as infection tissue/necrotic tissue/fungal infection tissue/tissues containing high viscous fluid/benign tumors/cancerous tumors), it increases the dispersion speed of the
  • chelators with [Zn ions/other transition metal ions]-holding feature are agents that help separate toxins/neurotoxins (the structure of toxins/neurotoxins needs to hold [Zn ions/other transition metal ions] to attach to host metalloproteins to cause poison) from the host's metalloproteins, neutralizing the toxicity of toxins/neurotoxins produced by pathogenic microorganisms/from outside the host body, so up to now, there are not pharmaceuticals whose active ingredients are chelators with [Zn ions/other transition metal ions]-holding feature to treat diseases caused by toxins/neurotoxins produced by pathogenic microorganisms/ from the outside entering the host body.
  • synthetic chelators are polyamine aminopoly carboxylate/Mg aminopolycarboxylate/Ca aminopoly carboxylate/salts made from polyamine with acid with the sulfur functional group in the molecule are substances that have the ability to quickly relieve symptoms/help the patient's body recover quickly, and the ability of the above synthetic chelators to quickly eliminate symptoms/help the patient's body recover quickly are greater than the abilities of natural chelators that present in the host body (mainly are histidine/lysine/arginine derivatives) dozens to hundreds of times, so until now there are no pharmaceuticals containing the above synthetic chelating agents to treat different symptoms/treat different diseases.
  • microorganisms that cause chronic diseases such as HIV/tuberculosis/other chronic diseases/cancer tissues in stage 3.4 are biological factories that release Zn/other transition metal-rich products which enter the host body continuously, leaving the host body in the condition of low quantity chelators with [Zn ions/other transition metal ions] -holding feature aways, causing the lack of these chelator to integrate into the Cu ions/Mg ions/Ca ions of the structure of antibacterial alkaline peptides/antibody proteins/microbicidal proteins inside leukocytes, makes antibacterial alkaline peptides/antibody proteins/microbicidal proteins inside leukocytes to reduce the ability to kill pathogenic microorganisms, and lacks chelators with [Zn ions/other transition metal ions]- holding feature to envelope Zn ions/other transition metal ions on the surface of pathogenic microorganisms/metastatic cancer cells that have left the cancer tissue to prevent path
  • Chelators as mentioned above also break Zn crosslinks/other transition metal crosslinks/Zn-other transition metal complex crosslinks in metalloproteins of telomeres during cell division, making the telomeres less likely to stick together at the end of the process of cell division, causing telomeres to shorten slowly, participating in increasing longevity for the elderly (the bodies of long-lived turtles are rich in polyamine derivatives, which helps them have a strong immune system and helps them live a long life and helps them not die when they eat food containing toxins/neurotoxins (such as eating rat poison), their eggs are rich in polyamine derivatives so they do not coagulate when boiled (animal semen of mammals/humans are rich in derivatives of spermidine/spermine, they do not coagulate when heated above 100 degrees Celsius), therefore, up to now, there are no pharmaceuticals with the active ingredient being chelators with [Zn ions/other transition metal ions] -holding feature to help increase the immune system/health/lifespan
  • Alzheimer's/Parkinson's disease after Alzheimer's/Parkinson's disease patients are exposed to diseases caused by microorganisms, and the condition of pharmaceuticals that prevent Alzheimer's/Parkinson's disease from aggravating by eliminating the agents that aggravate Alzheimer's/Parkinson's disease, and pharmaceutical situation that change conditions that aggravate the disease:
  • the physical structure of diseased tissues plays the role are structures that help protect pathogenic agents/pathogenic entities within these physical structures, and the situation of pharmaceuticals that make these physical structures to lose their ability to protect pathogenic agents/pathogenic entities within these physical structures:
  • the tight structure/structure containing high viscous fluid of diseased tissues are structures that protect pathogenic agents/pathogenic entities within these structures, and make the active ingredients to treat tissue diseases very difficult to thoroughly contact pathogenic agents/pathogenic entities within these structures, so up to now, there are no pharmaceuticals that creates strong enough physical effects in diseased tissues to help increase the speed of the active treatment ingredient disperses into the diseased tissue, and create thorough contact between the treatment active ingredient with pathogen agents/pathogenic entities within the treated tissue.
  • Transition metal ion crosslinks/transition metal ion Zn-other transition metal ion complex crosslinks locate between metal ions in metalloproteins of cancer cells/cancer syncytium/cancerous tissue that are continuously generation, and the situation of pharmaceuticals to treat cancerous tissues in the way that breaks these crosslinks:
  • cancer cells/cancer syncytium/cancer tissue that continuously increase in size are transition metal ion crosslinks/Zn ion-other transition metal ion complex crosslinks which located between metal ions in metalloproteins/between metalloproteins of [cancer cells/cancer syncytium/cancerous tissue] causing [cancer cells/cancer syncytium/cancerous tissue] to increase in size continuously; and unknown solution containing [chelators with strong [Zn ions/other transition metal ions] -holding feature + high concentration polyol] /solution containing [chelators with strong [Zn ions/other transition metal ions]-holding feature + high concentration polyol + peroxide (peroxide to create the foam structure for the treated tissue and oxidize the crosslinks mentioned above) when present in cancerous tissue, breaks a large number of the above crosslinks in cancer tissue (makes cancer cells to die/cancer syncytium to
  • chelators with [Zn ions/other transition metal ions] -holding feature are agents that cause microorganisms that already have the ability to resist antibiotics lose this ability, so up to now, there are no pharmaceuticals whose active ingredients are chelators with [Zn ions/other transition metal ions] -holding feature for use as the same time as antibiotics to kill microorganisms, causing the above diseases have lost their ability to resist antibiotics and to help reduce the dose of antibiotics needed to treat diseases caused by pathogenic microorganisms, so far it contains pharmaceuticals with the active ingredient being chelators with [Zn ions/other transition metal ions] -holding feature for use together with antibiotics to cause antibiotic-resistant pathogenic microorganisms to lose their resistance and to help reduce antibiotic doses antibiotics need to be used to treat diseases caused by pathogenic microorganisms, or there are no pharmaceutical in the form of [chelators with [Zn ions/other transition metal ions] -holding feature + antibiotics (
  • chelators with [Zn ions/other transition metal ions] -holding feature encapsulate [Zn ions/other transition metal ions] in metalloproteins on the surface of pathogenic microorganisms (on the surface of spike proteins of pathogenic viruses, for pathogenic viruses), causing pathogenic microorganisms to lose the ability to spread the disease to other hosts, so up to now, there are no drugs/no products for environmental treatment (sprayed into the environment/wipe on surfaces in environments with infectious diseases) containing the ingredient [chelators with [Zn ions/other transition metal ions]-holding feature + water] /[chelators with [Zn ions/other transition metal ions]-holding feature + propylene glycol/glycerol + water],
  • the foam structure contains [high concentration polyol + chelator agent + low water content] to increase the penetration speed of active ingredients of the pharmaceuticals into diseased tissues with the tight structure/structure containing high viscous fluid, and the situation of pharmaceuticals creating the foam structure containing [high concentration polyol + chelator + low concentration water] :
  • US patent application No. US20090030079A1 has the name of the patent application as "Use of trientine and penicilamine as countermeasure to metal contamination" by author Barry, Michael Wells, with the priority date of July 272007, in which methods are provided to minimize/pr event/ treat the negative effects of overexposure to metallic contaminants by using trientine or penicillamine or their derivatives, with contaminated metals due to the host being exposed to the source of metals in the environment.
  • the use of trientine or trientine derivatives in US patent application No. US20090030079A1 is unrelated to the pharmaceutical purposes of the patent application related pharmaceuticals containing Zn-holding chelator to treat symptoms/diseases caused by microorganisms/some other diseases...
  • US patent application No. US11033579B2 has the name of the patent application as "Use of trientine to deliver copper to ischemic tissue" by author Yujian Jame Kang, with the priority date is October 24, 2015, in which this invention provides a method of using trientine for the purpose of delivering Cu to ischemic heart tissues to increase intracellular Cu levels in heart tissue of patients with heart damage due to ischemic heart tissue.
  • the use of trientine or trientine derivatives in this patent application is unrelated to the pharmaceutical purposes of the patent application related pharmaceuticals containing Zn-holding chelator to treat symptoms/diseases caused by microorganisms/some other diseases...
  • Some inventions use metal chelates to inhibit the proliferation of microorganisms:
  • pathogenic microorganisms including pathogenic fungi
  • Zn chelates do not have this ability, meaning is the proposed method of inhibiting the proliferation of microorganisms including bacteria and fungi by using Zn chelate of the above invention which cannot yield practical results (according to the experiments/theory of the application patent).
  • the Chinese patent application number CN2006100154378A with the French name "Composition antibioti comlois des betalacamines et des agents chelados ionniques", by author Hesheng Zhang, which proposes an antibiotic compound consisting of at least at least one P-lactam antibiotic and at least one ionic chelate, and the antibiotic compound comprises at least one P-lactam antibiotic and at least one ionic chelate with the ionic chelate being EDTA disodium, and the compound this antibiotic requires a P-lactam antibiotic combined with a chelate ion to create an antibiotic that is more effective than a P-lactam antibiotic.
  • EDTA disodium is used, EDTA disodium is quite toxic to host cells (host is animal/human). Experiments keeping Boraras Micros fish in water with 300 ppm EDTA disodium, showed that the fish died in less than 24 hours; while keeping Boraras Micros fish in water with 800 ppm EDTA Cu/3000 ppm EDTA Mg/12000 ppm EDTA Ca, fish did not die after 10 days.
  • EDTA disodium (as well as EDTA dipotassium) is toxic to host cells due to their non-selective of holding of metal ions due to EDTA disodium holding Mg ions/Ca ions/Cu ions/Fe ions/Zn ions/other heavy metal ions too tightly, whereas metalloproteins of healthy animal/human cells require Mg ions/Ca ions/Cu ions/Fe ions/Zn ions/other heavy metal ions in active form (not be enveloped by chelator types which hold them too tightly) so that the host's healthy cells can function normally.
  • chelating agents metal ion chelating agents
  • [Zn derivatives/other transition metal derivatives/other Zn-rich peptides and other transition metal-rich peptides/other Zn-rich proteins and other transition metal-rich proteins] are [Zn/other trasition metal-rich products] transitions] that bind to host metalloproteins, causing symptoms and producing the post-disease syndrome and provide a source of Zn/other transition metal materials for secondary pathogenic microorganisms, and secondary pathogenic microorganisms use high concentrations of [Zn ions/other transition metal ions] on their surfaces to adhere to metalloproteins on the surface of host cells/receptors on the host cell membrane, so up to now, there are no pharmaceuticals containing chelators with [Zn ions/other transition metal ions] -holding feature work by these chelators (of chelator drugs) that separate [Zn/other transition metal] -rich products and separate path
  • the invention has found many to treat many different diseases/many different syndromes, especially pharmaceuticals to treat diseases caused by microorganisms of the invention, has the effect of quickly eliminating symptoms, and causing microorganisms to lose their ability to attach to host cells, and quickly weakening pathogenic microorganisms, and strengthening the host's immune system, and prevents the appearance of post-disease syndrome.
  • diseased tissues such as infected tissue/necrotic tissue/fungal tissue/benign tumors/cancerous tumors
  • these pharmaceuticals contain agents that create strong physical effects in treated tissues/ create the foam structure for treated tissues, so these pharmaceuticalscause the active ingredients of the pharmaceutical to overcome the tight structure/ structure containing highly viscous fluid of the diseased tissues which are the structure protects the pathogenic agents/pathogenic entities inside the diseased tissue, making the speed of dispersal of the active ingredients of the pharmaceutical in the treated tissues faster than that of contemporary pharmaceuticals(which do not produce physical effects/does not produce sufficiently strong physical effects/does not create the foam structure in the treated tissue) from dozens to hundreds of times, thanks to which these pharmaceuticalsof the present invention are effective outstanding treatment of diseased tissues.
  • Electrodes pairs [Zn-Cu/Zn- Mg/Zn-Ca/Zn-Fe/Zn-Mn//Zn-Ni/ Zn-Co/Zn-Pd/Zn-Pb/Zn-Hg... ] electrode pairs [Zn- other metals can be in metallic form or in the form of insoluble metal derivatives), and the formation of these complexes generates electric current during the formation of these complexes and changes the redox properties around these complexes during the formation of these complexes.
  • these polyamine derivatives are chelators with [Zn ions/other heavy metal ions]-holding feature), this depletion is due to these chelators fully held Zn derivatives released from pathogenic microorganisms and from fragments of pathogenic microorganisms, and because these chelators fully held [Fe ions/Cu ions/Zn ions/other heavy metal ions] from host cell/host red blood cell fragments (attacked by pathogenic microorganisms); -in conditions where the host body is depleted of these chelators, the Zn ions of these Zn derivatives will attach to the metal ions in the structure of peptides (soluble)/proteins (soluble) in the blood/alveolar fluid/ tissue fluid, generates Zn-peptide complex suspension/Zn-protein complex suspension, causing symptoms of thick blood/thick tissue fluid/thick alveolar fluid; - in conditions of the host body is depleted of these chelators, pathogenic microorganisms will easily accumulate Zn ions/other
  • the bond force of the Cu ion-Fe ion complex is the strongest, can recognize the existence of Cu ion-ion Fe ion complex/Cu ion-Zn ion complex/Cu ion-Mg ion complex/Cu ion-Ca ion complex, and can recognize Cu ion-other metal ion bonds, in which the Cu ion-Fe ion bond is the bond type with the highest magnitude through experiments conducted in water environment (water environment without chelators with [Zn ions/other transition metal ions] -holding) is the environment that simulates the blood environment/alveolar fluid environment of a host with the depletion of these chelators), these experiments were performed by adding an excess amount of 1% Na ascorbate solution to the test tube containing the solution with [0.1 % CuC12 + greater than 0.2% FeC13]/ the test tube containing the solution containing [0.1 % CuC12 + greater than 0.6% ZnC12
  • [Cu ions/Zn ions/other heavy metal ions] holding feature (referred to as chelator drugs) (such as EDTA Mg/DTPA Mg/EDTA Ca/DTPA Ca/triethylenetetramine diethylenetriaminepentaacetate) to promptly save patients from death by acute respiratory failure symptoms.
  • chelator drugs such as EDTA Mg/DTPA Mg/EDTA Ca/DTPA Ca/triethylenetetramine diethylenetriaminepentaacetate
  • Pathogenic microorganisms are living entities that grow rapidly (such as organic matter decomposing microorganisms/pathogenic microorganisms/pathogenic microorganism syncytial/cancer cells/cancer syncytial/cancerous tissues...), so they have a high demand for Zn and other transition metals, the proteins of pathogenic microorganisms are rich in cysteine, which helps these proteins accumulate Zn ions/other transition metal ions, making their proteins (especially the proteins on their surfaces) are rich in Zn/other transition metals).
  • the first stage is the pathogenic microorganisms stage and their fragments release [Zn derivatives/other transition metal derivatives/Zn- other heavy metal complex derivatives/Zn-other heavy metals-rich peptides and proteins (referred to as are [Zn/other transition metals] -rich products from pathogenic microorganisms, and [Zn/other transition metal] -rich products from pathogenic microorganisms that are also toxins/neurotoxins) into [host blood/tissue fluid/alveolar fluid], at this stage, chelators with [Zn/other transition metals] holding feature in the host body are still abundant (not including people with weakened immune systems/the elderly), so [Zn/other transition metals]-rich products present in the host body holding [Zn ions/other heavy metal ions] of [Zn/other transition metals]-rich products from pathogenic microorganisms
  • the second stage is the stage in which the above- mentioned chelators in [blood/tissue fluid/alveolar fluid] are depleted due to the holding of [Zn ions/other transition metal ions] of Zn-rich products/ other transition metals-rich products from pathogenic microorganisms, and under conditions of depletion of these chelators, Zn-rich products/ other transition metals-rich products from pathogenic microorganisms and pathogenic microorganisms easily attaches to the host's metalloproteins, causing symptoms/toxicity to host cells and host tissues, host nervous tissue, and host brain tissue, causing disease in the host and causing post-disease syndrome for the host (in some diseases, such as post-Covid syndrome).
  • Products rich in [Zn/other transition metals] from pathogenic microorganisms when attached to host metalloproteins, generate various symptoms (such as fatigue/fever/rash/drainage nose/red eyes/diarrhea/mucus thick... )/various neurological symptoms (such as loss of taste/loss of smell/loss of appetite/sore throat/muscle pain/joint pain/headache...
  • the abundance of Zn derivatives/Zn- other heavy metal complex derivatives as mentioned above also causes the accumulation of Zn ion/Zn ion-other heavy metal ion complexes in tissues/nerve tissues/brain tissue, giving rise to post-disease syndrome (such as post-Covid syndrome in people who have had Covid disease and their bodies go through a long period of depletion of the chelators as mentioned above).
  • the suspension composed of Zn-blood-complexes will appear in the blood, with very low concentrations of Zn derivatives (below 0.7- 1.5 ppm calculated as Zn) is enough to form the Zn- blood-complex suspension, and chelators with [Zn ions/other heavy metal ions]-holding feature are capable of dissolving the Zn-blood-complex suspension (at neutral to alkaline pH).
  • polyamine aminopolycarboxylate such as polyamine aminopolycarboxylate is made from polyamine which polyamine is Triethylenetetramine/ Tetraethylenepentamine/ Pentaethyl enehexamine/Poly ethyl enimine branched with aminopolycarboxylic acid is Ethylenediaminetetraacetic acid (EDTA)/Diethylenetriaminepentaacetic acid (DTP A)/ triethylenetetramine-N,N,N', N",N"',N"'- hexaacetic acid (TTHA)/Dibenzothiophene-1,3,6,8- Tetracarboxylic acid (DTCA)/ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'- tetraacetic acid (EGTA)/l,2-bis(2- aminophenoxy)ethane-N,N,N',N'-tetra- acetic acid
  • polyamine aminopolycarboxylate when have the concentration in [blood/tissue fluid/alveolar fluid] of the host are quite low (over 30 ppm for polyamine aminopolycarboxylate made from TEPA/PEHA/branced PEI with DTPA), and above 60 ppm for polyamine aminopolycarboxylate formed from TETA with DTPA), the ability to inhibit/kill pathogenic bacteria far exceeds this ability of Bactrim with the concentration of 10 ppm/ Ampicillin with the concentration of 20 ppm in host [blood/tissue fluid/alveolar fluid],
  • pharmaceuticals with the ingredients [polyamine aminopolycarboxylate + antibiotic active ingredient] / [polyamine aminopolycarboxylate + salt made from polyamine with at least one acid with the sulfur functional group in molecule] are pharmaceuticals that kill pathogenic microorganisms very strongly, Therefore, they are outstandingly effective pharmaceuticals in treating diseases caused by pathogenic microorganisms, and helps to greatly reduce the doses of active ingredients of antibiotics/not having to use antibiotics, while also bringing a series of other benefits as mentioned above (such as quickly reducing symptoms/ cleansing the body from the accumulation of [Zn ion accumulation/ other transition metal ions]/relieving pain and inflammation).
  • Zn-rich derivatives (simulating Zn-rich products from pathogenic microorganisms) as agents that generate the symptoms of loss of taste and various symptoms (such as in Covid 19/influenza/diseases caused by pathogenic microorganisms): -the symptom of loss of taste caused by Zn derivatives can be identified by chewing and sucking a 15 mg Zn gluconate tablet and spitting it out after 120 seconds, then tasting the solution [15% sucrose/aspartame sweet enough /sucralose sweet enough], the sweet taste sensation on the tongue is completely lost; then suck the solution [5% arginine glutamate/0.5% triethylenetetramine glutamate] for 10 seconds and taste the solution again [15% sucrose/aspartame sweet enough /sucralose sweet enough], resulting in the sweet taste on the tongue are fully recovered.
  • the biological significance of these discoveries is that when the diseased bodies (body suffering from diseases caused by pathogenic microorganisms)/ diseased tissues (infected tissues/inflammatory tissues) are depleted of the above chelators, the diseased bodies/diseased tissues/pain tissues/inflammation tissues, then after the above chelators are present in the diseased bodies/diseased tissues, thanks to the introduction of the present invention pharmaceuticals containing the above chelators into the diseased bodies/diseased tissues, will reduce pain/inflammation in the diseased bodies/diseased tissues.
  • the mechanism of the reducing of inflammation/pain be above chelators is that they hold metal ions such as Cu ions/Zn ions/Fe ions/other metal ions (i.e.
  • the biological significance of the above discoveries related to voltage is that when the diseased bodies (bodies suffering from diseases caused by pathogenic microorganismsj/diseased tissue (infected tissue/inflammatory tissue)) are depleted of above chelators, generates pain/inflammation in the diseased bodies/diseased tissue, then after above solution of [peroxide/high concentration glycerol/[high concentration glycerol + peroxide] present in the diseased bodies/diseased tissues thanks to the introduction of the present invention pharmaceuticals containing [peroxide/glycerol with high concentration glycerol/[glycerol with high concentration glycerol + peroxide] into the diseased bodies/diseased tissues, will reduce pain/inflammation in the diseased bodies/diseased tissues.
  • the mechanism of reducing the inflammation/pain of high concentrations of glycerol in diseased tissues is that glycerol reduces the polarity of diseased tissues, causing high voltage currents (in conditions of depletion of the above chelators) in the electrode pairs in the metalloproteins in diseased tissues, thereby helping to reduce pain/inflammation.
  • the mechanism of reducing of the inflammation/pain of peroxides in diseased tissues is peroxides oxidize metal ion complex crosslinks (such as crosslinks of Zn- Fe complex/Cu-Fe complex/Zn-Cu-Fe complex%) in the structure of metalloproteins of pathogens (such as pathogenic microorganisms/ cancer cells/toxins), cause these crosslinks to break and to convert into insoluble metal oxides, thereby reduce the voltage of the electrode pairs in the diseased tissues, helping to reduce pain/inflammation.
  • diseased tissues such as infected tissues/necrotic tissues/cancerous tissues/tissues containing much polar fluid
  • metal ion complex crosslinks such as crosslinks of Zn- Fe complex/Cu-Fe complex/Zn-Cu-Fe complex
  • pathogens such as pathogenic microorganisms/ cancer cells/toxins
  • Another important biological significances of the present invention pharmaceuticals containing [high concentration glycerol + peroxide]/[high concentration glycerol + peroxide + chelator] is the ability to treat diseased tissues (such as bactarial infection tissues/fungal infection tissues/necrotic tissues/dark-colored benign tumors/cancerous tumors (cancerous tissue)/diseased tissues containg high polarizationfluid tissues”) with very high treatment effectiveness and very short treatment time (less than 24 hours to several days (several days for large-volume cancer tissues), by injecting small doses sequentially into different locations in large-volume cancer tissue), thanks to the pharmaceutical causing the diseased tissue to have the foam structure containing substances that promote the absorption of active ingredients of the drug, thanks to that, pathogens [pathogenic microorganisms/cancer cells that are rich in H2O2 decomposition catalysts]/toxins that are also rich in H2O2 decomposition catalysts] are quickly killed/destroyed, while healthy cells remain safe due to healthy cells
  • the invention has found a series of new elementary biological foundations in the biological world, and based on these elementary biological foundations, the invention has developed the pharmaceutical type with active ingredient being chelators with [Zn ions/ other transition metal ions] holding feature (referred to as chelator drugs) to treat the symptoms as mentioned above/diseases as mentioned above/syndromes as mentioned above,
  • chelator drugs operate by mechanisms completely different from those of contemporary pharmaceuticals for the treatment of above symptoms /above diseases/above syndromes.
  • the present invention chelator pharmaceuticals aim to precisely attack pathogenic agents/pathogenic entities, therefore, the present invention chelator pharmaceuticals have outstanding effectiveness in disease prevention/ disease treatment, and thanks to that, the pharmaceuticals have the ability to save lives in severe cases/critical cases of most diseases caused by pathogenic microorganisms, including dangerous diseases with high/very high mortality rates, especially the present invention chelator pharmaceuticals are very effective in treating cases of difficulty breathing/respiratory failure/acute respiratory failure in diseases caused by microorganisms.
  • the chelators of the present invention chelator pharmaceuticals have the following effects and the mechanisms of action as following:
  • diseased tissues are bacterial infection tissues/necrotic tissues/fungal infection tissuea/tissues containing fluid with many toxins (tissue with proliferating cells)/benign tumors/cancerous tumors (tissue with cancerous cells);
  • infectious diseases are easily spread by using the active ingredients of chelators (mainly Ca aminopolycarboxylates) to create environmental treatment products that help prevent the spread of infectious diseases;
  • chelators mainly Ca aminopolycarboxylates
  • immune systems are easily weakened when the host is infected with diseases caused by microorganisms by using the active ingredient of the chelators to introduce into products which are beverages/processed foods/spices/prepared food/vitamin supplements/various medications.
  • the invention has developed the pharmaceutical type which contains chelators and agents that creates strong physics effects in diseased tissues to treat the diseased tissues (referred to as chelator -strong physics effect pharmaceutical type) with the active ingredients are [chelators with [Zn ions/other transition metal ions] -holding feature + agents that produce strong physics effects in diseased tissue (such as glycerol at high concentrations) + low water content] to treat diseased tissues (such as bacterial infection tissues/necrotic tissues/fungal infection tissues/ diseased tissue containing fluid with many toxins/benign tumor s/cancerous tumors).
  • chelator -strong physics effect pharmaceutical type with the active ingredients are [chelators with [Zn ions/other transition metal ions] -holding feature + agents that produce strong physics effects in diseased tissue (such as glycerol at high concentrations) + low water content] to treat diseased tissues (such as bacterial infection tissues/necrotic tissues/fungal infection tissues/ diseased tissue containing fluid with many toxins/b
  • This pharmaceutical type works by the mechanism of losing the ability to protect pathogenic agents/pathogenic entities in diseased tissues, which are tight structures/structures containing highly viscous fluid which these structures make the speed of dispersing the treatment ingredients in the treated tissues very slow, making the treatment of these diseased tissues difficult (especially for large volume diseased tissues).
  • This pharmaceutical type produces a series of physics effects in the treated tissue that provide a series of benefits for the treatment of diseased tissues, these benefits are:
  • this pharmaceutical type is very effective in treating diseased tissues and help get a short time for treatment, while contemporary pharmaceuticals do not contain chelators with strong [Zn ions/other transition metal ions] -holding feature and do not contain agents that produce strong physics effects in the treated tissue, so contemporary pharmaceuticals that treat diseased tissues have many difficulties in treating diseased tissues (especially for large- volume diseased tissues).
  • the invention has developed the pharmaceutical type that not only creates a series of effects and strong beneficial physics effects in the treated tissue as mentioned above, and also gives the treated tissue the foam structure, help causes pathogenic agents/pathogenic entities to locate in the thin walls created between tiny air bubbles and help create many other beneficial physics effects (such as the change in pressure of air bubbles continuously, helps increase the penetration of active ingredients into pathogenic agents/pathogenic entities that located in thin walls).
  • the pharmaceuticals contains ingredients including [chelators with strong [Zn ions/other transition metal ions] -holding feature + agents that promote the speed of penetration into the treated tissue (such as high concentrations of glycerol) + agents that create the foam structure for the treated tissue being peroxide + low concentration water] (referred to as chelator -foam -strong physics effect pharmaceutical to treat diseased tissues (such as bacterial infection tissues/necrotic tissues/fungal infection tissue/ disease tissues containing fluid with many toxins/benign tumors/cancerous tumors), chelator -foam -strong physics effect pharmaceuticalshave the same effects as chelator -strong physics effect drug mentioned above, at the same time, they have the additional effects as following:
  • the present invention pharmaceuticals have the active ingredients that are chelators with strong [Zn ions/other transition metal ions] -holding feature + (referred to as chelatordrugs), in which, which chelators with strong [Zn ions/other transition metal ions]-holding feature can hold more [Zn ions/other transition metal ions], those chelators have the more effective in [relieving symptoms of diseases caused by microorganisms/relieving post-disease syndromes/treating diseases caused by pathogenic microorganisms/treating diseases caused toxins and neurotoxins/treating cancers/treating weakened immune systems in chronic diseases (such as HIV/tuberculosis/chronic lung infections/chronic diseases of other diseases caused by pathogenic microorganisms/treating cancer stage 3.4/tr eating of weakened immune system in the elderly/treating the syndromes in the elderly/treating the secondary diseases caused by secondary pathogenic microorganisms... ], chelators with strong [Zn ions/other transition metal ions]- holding feature present
  • -polyamine aminopolycarboxylate is made up of polyamine which polyamine is Triethylenetetramine (TETA)/ Tetraethylenepentamine (TEPA)/ Pentaethylenehexamine (PEHA)/ Branched polyethylenimine (branched PEI) with aminopolycarboxylic acid which aminopolycarboxylic acid is Ethylenediaminetetraacetic acid (EDTA)ZDiethylenetriaminepentaacetic acid (DTP A) / triethylenetetramine-N,N,N',N",N"',N"'- hexaacetic acid (TTHA)/Dibenzothiophene-1,3,6,8- Tetracarboxylic acid (DTCA)/ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'- tetraacetic acid (EGTA)/l,2-bis(2- aminophenoxy)ethane-N,N,N',N'-tetra
  • -Mg aminopolycarboxylate/Ca aminopolycarboxylate is made up of [Mg derivative/Ca derivative] with aminopolycarboxylic acid as [EDTA/DTPA/TTHA/DTCA/EGTA/BAPTA/NOTA/DOTA//HEEDA//PEPA/HEHA/TETA /TETPA/DOTPA/DOTMP/EDDS/HEIDA/GLDA/MGDA/ASDA/CDTA/EDDS/EDDHA/DOT A/EGTA/NETA/CyDTA/GEDTA/TTHA/DO3 A/ AAZTA] ;
  • the salt made up of polyamine with acid that has the sulfur-containing functional group in the molecule is the salt made up of the polyamine [TETA/TEPA/PEHA/PEI branches] with the acid that has the sulfur-containing functional group in the molecule that is [sulfonic acid/sulfuric acid /sulfurous acid/sulfenic acid/sulfinic acid/hydrogen sulfide acid/hyposulfurous acid];
  • salt made from polyamine with acids having at least 2 carboxyl-containing functional groups in the molecule are salts made from polyamines [TETA/ TEPA/PEHA/HEPA/HEEDA/ /PEPA/PEI/ branched PEI] with acids having at least at least 2 carboxyl-containing functional groups in the molecule are [gluconic acid/fumaric acid/itaconic acid/glutamic acid/aspartic acid/carbonic acid/phosphoric acid/citric acid/succinic acid/malic acid];
  • salts made from polyanine with acids having at least 2 hydroxyl-containing groups in the molecule are salts made up from polyamines are TETA/TEPA/PEHA/branche PEI] with acids having at least 2 hydroxyl-containing functional groups in the molecule are ascorbic acid/ gallic acid/tannic acid;
  • One unit of the above synthetic chelator of the chelator pharmaceuticals is capable of holding 80 units to more than 200 units of [Zn ions/other transition metal ions], while on unit natural chelator (such as one unit of lysine phosphate/lysine chloride/arginine phosphate/arginine chloride) is capable of holding one unit (or few units) of [Zn ions/other transition metal ions], these help to understand that the chelators of the present invention chelator pharmaceuticals have the ability to quickly relieve symptoms/to prevent the appearance of post-disease syndromes/to weaken pathogenic microorganisms/to strengthen the immune system/to prevent the cancer metastasis/to inactivating toxins and neurotoxins/to recover the host body from many different diseases... far excess of these abilities of natural chelators which present in the host body.
  • Chelators of chelator pharmaceuticals/ chelator - strong physical effect pharmaceuticals / chelator - foam-strong physical effect pharmaceuticals of the present invention when present in the host body/diseased tissues of the host have the following effects and have mechanisms of action as following: • make to rapidly lose the symptoms in diseases caused by pathogenic microorganisms (including dangerous symptoms/dangerous neurological symptoms), thanks to chelators of drug to separate [Zn/other transition metals] -rich products (released from pathogens and their fragments, referred to as from pathogenic microorganisms) which are [toxins/ neurotoxins] and are the agents that cause symptoms from the host metalloproteins, and then chelators hold [Zn/other transition metal-rich products] which are removed from patient's body through urine;
  • Mg-porphyrin and these new chelators help gradually separate [Zn/other transition metal] -rich products from pathogenic microorganisms from host metalloproteins, gradually reducing the intensity of symptoms, helps the host body recover, however, the recovery by these new natural chelators takes a long time (weeks to months for unvaccinated patients) and as [Zn/other transition metal] -rich products from pathogenic microorganisms are not completely separated from the host metalloproteins by these new chelators, causing post-disease syndrome.
  • the present invention chelator pharmaceuticals contain chelators with very strong [Zn ion/other transition metal ion] holding feature, which can be detected through one chelators unit of the present invention chelator pharmaceutical can dissolve 80 units to 200 units of the suspension composed of Zn-blood complex, while natural chelators are present in the host, must be required about 100 units of natural chelators to dissolve 100 units of suspension composed of Zn-blood complex (as mentioned in the background of invention), this ability of the chelators of the present invention chelator pharmaceuticals helps to understand why the present invention chelator pharmaceuticals cause rapid disappearance of symptoms in serious cases of diseases caused by pathogenic microorganisms surprisingly (such as Covid 19 (on human)/influenza ( on human)/viral fever ( on human)/avian influenza (clinical trial on chicken), with symptoms significantly reducing approximately 3-4 hours after taking the first oral dose/approximately 20 minutes after the first injection dose, and the patient achieves the pleasant felling clearly, while before using the present invention chelator pharmaceuticals the patient
  • the pharmaceutical to treat Covid 19 with each dose for adults contains 1.4 g Mg EDTA / 0.8 g tri ethylenetetramine diethylenetriaminepentaacetate, the pharmaceutical is taken 3 times a day for 7 days, and is taken 1/2 above doses for next 8 days to prevent the occurrence of post-Covid syndrome, resulting in patients with severe Covid- 19 (including patients who have not received any Covid- 19 vaccine shot/patients who are older than 75 years old), 4 hours later after taking the first dose, the symptoms were significantly reduced, after 48 hours the remaining symptoms were negligible, the next few days the disease was cured, and after treatment, the post-Covid syndrome did not appear.
  • present invention chelator pharmaceuticals for the treatment of above diseases, along with the clinical treatment effectiveness on animals that are infected with toxins/neurotoxin as mentioned in above background of invention, help predict the present invention chelator pharmaceuticals especially drugs whose contain chelators being polyamine aminopolycarboxylate (such as polyamine aminopolycarboxylate made from [TETA/TEPA/PEH A/PEI branched with EDTA/DTPA/TTHA/DTCA /EGTA/BAPTA/NOTA/DOTA//HEEDA//PEPA/HEHA/TETA/TETPA/DOTPA/DOTMP/EDD S/HEIDA/GLDA/MGDA/ASDA/CDTA/EDDS/EDDHA/DOTA/EGTA/NETA/CyDTA/GEDT A /TTHA/D03A/AAZTA] which are the pharmaceuticals that can promptly save the lives of severe cases/critical cases of dangerous diseases caused by microorganisms with high/very high mortality rates (such as
  • the active ingredient polyamine aminopolycarboxylate such as polyamine aminopolycarboxylate which is made from [polyamine is TETA/TEPA/PEHA/PEI branched with aminopolycarboxylic acid is EDTA/DTPA/TTHA/DTCA/EGTA/BAPTA/NOTA/DOTA//HEEDA//PEPA/HEHA /TETA/TETPA/DOTPA/DOTMP/EDDS/HEIDA/GLDA/MGDA/ASDA/CDTA/EDDS/EDDHA /D0TA/EGTA/NETA/CyDTA/GEDTA/TTHA/D03A/AAZTA] are chelators that have the effect of loss of toxicity of toxins/neurotoxins (including toxins/neurotoxins produced by pathogenic microorganisms in the patient's body and external toxins/external neurotoxins, such as from rat poison/pesticides/venoms of poisonous animals/poisonous plants/poisonous mushrooms/
  • drugs with the ingredients [polyamine aminopolycarboxylate + antibiotic active ingredient] / [polyamine aminopolycarboxylate + salt made from [polyamine with acid having the sulfur-containing functional group in molecule] are pharmaceuticals that kill bacteria very strongly, therefore, they are the outstandingly effective pharmaceuticals in the treatment of diseases caused by pathogenic microorganisms, and help greatly reduce the doeses of active ingredients of antibiotics/do not have to use antibiotics, and at the same time, these pharmaceuticals bring a series of other benefits as mentioned above (such as quickly reducing symptoms/ cleansing the patient body from the accumulation of Zn ion or other transition metal ions/reducing pain and inflammation).
  • chelator-strong physics effect pharmaceutical containing [70% glycerol + 0.4% EDTA Cu + 1 ,2 g EDTA Mg + 3.6 g EDTA Ca + 100% water] onto open wound on infected tissue (apply 4 times a day for the first days, and 2 times in the following days, and apply until the open wound heals (about 5-7 days), the infection is significantly reduced after 1 day, after 3 days the infection is gone, after 5 to 7 days the open wound heals with little scarring, the pharmaceutical generates the pain relief effect (only creates the mild burning sensation on open wounds for the first few minutes after application).
  • Chelator -foam-strong physics effect pharmaceutical type has the effects of Chelator -strong physics effect pharmaceutical type, in addition the chelator -foam-strong physics effect pharmaceutical type also has the following effects and benefits:
  • Chelator-strong physics effect pharmaceutical type has the effects of chelators of parmaceutical type in treated tissues, in addition the Chelator-strong physics effect pharmaceutical type also has the following effects and following benefits:
  • These pharmaceuticals contain ingredients including:: -[chelator with [Zn ions/ other transition metal ions] -holding feature + agents that promote the speed of the penetration of treatment ingredients in the treated tissue (such as high concentrations of glycerol) + low water content] (referred to as chelator -strong physical effect pharmaceutical); - [chelator with [Zn ions/other transition metal ions] -holding feature + agents that promote the speed of the penetration of treatment ingredients in the treated tissue (such as high concentrations of glycerol) + agents creates the foam structure for the treated tissue (such as peroxides_+ low water content] (referred to as chelator-foam-strong physical effect pharmaceutical); these two pharmaceuticals are used for the treatment the diseased tissues (such as bacterial infection tissues/necrotic tissues/fungal infection tissues/ diseased tissues containing fluid with many toxins/benign tumors/cancerous tumors), these two pharmaceutical types have the following effects as the chelator pharmaceutical type, at the same time, they have additional effects (as mentioned
  • -Chelator pharmaceuticals to treat Covid 19 disease treating patients with severe symptoms and patients who have not received any Covid 19 vaccine shots, patients are given the oral pharmaceutical (with each dose (adult dose) containing [1.4 g EDTA Mg (6% Mg type)] + 2.6 g water + glycerol to make 5 ml)] (about a tea spoon), the drug is taken 3 doses per day , and take for 7 days, and from the 8th to the 15th day take 1/2 of the above dose every day (take for an additional from 8 days to prevent the appearance of post-Covid syndrome), the result of 4 hours after taking the first dose is the symptoms that are clearly reduced and the patients become much more pleasant, after 48 hours, the symptoms remains negligible, then after a few days later, the disease was cured, and after treatment, the patient did not have post-Covid 19 syndrome.
  • the chelator pharmaceutical to treat the influenza for the 63 -year-old patient with severe symptoms the patient was given the chelator pharmaceutical with each dose (adult dose) containing [1.4 g EDTA Mg (adult dose). 6% Mg)] + 2.6 g water + glycerol enough 5 ml)] (about a tea spoon), the pharmaceutical is taken 3 doses per day, and taken for 7 days, 3 hours after taking the first dose, most of the symptoms were significantly reduced and the patient felt much better, and after 36 hours most symptoms were gone, and after 5 days the disease was over.
  • the chelator pharmaceutical o treat the viral fever for the 8-year-old patient with severe symptoms, the patient was given the chelator pharmaceutical with each dose (dose for children is about 30 kg) containing (1/2 the dose compared to adult dose) [0.7g EDTA Mg (6% Mg type)] + 1.3 g water + glycerol enough 2.5 ml)] (about 1/2 a tea spoon), the pharmaceutical is taken 3 doses per day, and took for 7 days, the result is the patient's fever decreased and after 3 hours after taking the first dose, the patient returned to active play and eating as before disease suffering, and the disease is cured after 5 days.
  • the chelator pharmaceutical to treat the avian influenza in chickens suffering avian influenza (influenza virus strain is not undetermined), with the chicken flock has many individuals that were lethargic state and many chickens began to die, 10% of chicken flock were kept for control experiments and given normal water, 90% of chicken flock were given water with 3% Mg EDTA, results after 12 hours the chickens that drank water containing 3% Mg EDTA, they stopped the lethargic state and they returned to eating normally, while the control chickens continued the lethargic state and stopped eating.
  • the chelator pharmaceutical agent to treat the long Covid syndrome after recovering from Covid 19, with the case of long Covid syndrome is the 57-year-old man who had previously had Covid 19 and had received 3 shots of Covid 19 vaccine previously, with symptoms of walked up the stairs to the 4th floor, breathing much faster than before he suffered the Covid 19, after using for 4 weeks the chelator pharmaceutical with each dose (adult dose) containing [[0.3 g triethylenetetramine neutral glutamate + 0.6 g EDTA Mg], and took it twice a day, after 4 weeks of taking the medicine, he walked up the stairs to the 4th floor without the rapid breathing, and breathing returns to normal like before Covid 19.
  • the chelator pharmaceutical to treat the toothache symptoms in toot cavities by using the cotton gauze pad wrapping around the powder of the chelator pharmaceutical containing [20% Ca EDTA powder + 80% zeolite powder] and inserted into the tooth cavity, the result is that after about 10 minutes, the toothache symptoms gradually decrease and the pain disappears after about 15 minutes.
  • the chelator pharmaceutical to treat the symptoms of loss of taste in Covid 19 disease, by sucking the drug solution containing 2% Ca EDTA for a few minutes and then spit it, the results is the sweet taste to recover immediately afterwards, obvious recovery for the loss of taste of sweeteners generated by cane sugar/aspartame/sucralose.
  • the chelator pharmaceutical to treat the symptoms of sore throat/cough in diseases caused by microorganisms by lozenging candy with each 2g candy containing [0.3 g Ca EDTA + 0.6 glycerol + 1g gelatine + water just enough 2g], the result is that after sucking for about 10 minutes, the symptoms of sore throat/cough are reduced, after many times of sucking (a large number of these chelator pharmaceutical candies can be sucked for 24 hours, due to CA EDTA is highly safe when used in high doses (adults can use under 120g of Ca EDTA in 24 hours with 20g for each time and 4 hours apart, still have no side effects).
  • the chelator pharmaceutical to treat the symptoms of dry eyes/eye pain/red eyes by instilling into the eyes the chelator pharmaceutical solution containing [0.1% tri ethylenetetramine di ethyl enetriaminepenatacetate (neutral) + enough 100% water) can be instilled from 2 to 6 times a day, the result is after a few minutes of instilling the above solution, the symptoms of dry eyes/eye pain will no longer exist and the symptoms of red eyes will decrease after a few hours.
  • the chelator pharmaceutical to treat the symptoms of headaches of unknown cause by taking chelator pharmaceutical with each dose (adult dose) containing 0.5 g of tri ethylenetetramine diethylenetriaminepenatacetate (may be in pill form), the result is after about 2 hours, the headache symptoms will be significantly reduced.
  • the post-Covid syndrome of this patient was treated with the chelator pharmaceutical with each dose containing [0.5 g Mg EDTA + 1g glycerol + 2g of water], taking twice per day for 1 month, the result is that after 1 week, the shortness of breath during vigorous exercise is significantly reduced, and after 1 month of treatment, the shortness of breath during vigorous exercise is no longer present, and the treated person feels as pleasant as before Covid 19 disease.
  • the chelator pharmaceutical to treat the disease caused by toxin with the toxin is rat poison having the active ingredient being flocoumafen, feed the mice in cages the pills containing flocoumafen, and 12 hours later place in the mouse cage the cup of water solution having the chelator pharmaceutical containing the active ingredient being 0.3% tri ethylenetetramine diethylenetriaminepenatacetate, the result is that after many days the mice still lived, while in the control cage keeping the mice which were fed the above rat poison, but the water cup is just normal water, the result is all the mice died after about 2 days.
  • the chelator pharmaceutical to treat the the diseases caused by toxins/neurotoxins by keeping Boraras Micros fish in water containing the chelator pharmaceutical with the active ingredient being triethylenetetramine diethylenetriaminepenatacetate, the clinical trials on animals (such as Borara Micros fish) were performed and achieved as the following results: keeping fish in water with [5 ppm Nereistoxin + 50-300 ppm tri ethylenetetramine di ethylenetriaminepentaacetate], fish lived for many days (up to weeks), while keeping fish in water with 5 ppm Nereistoxin, fish died after 30 minutes; keeping fish in water with [1.25 ppm flocoumafen (1/4 tablet of rat poison (with 0.005% flocoumafen) in 1 liter of water) + 50-300 ppm triethylenetetramine di ethylenetriaminepentaacetate], fish lived for days (up to weeks), while keeping fish In water with 1.25 ppm flocoumafen, fish died after 36 hours; keeping
  • the chelator -physics effect pharmaceuticals (the chelator -physics effect drugs) to treat the severe bacterial infection tissues (on human) that have been previously treated with multiple antibiotics (topical and oral) for over 1 week without improvement, these bacterial infection tissues are treated by applying the above pharmaceutical solution to the open wound on the bacterial infection tissues with 4-6 times/day for 7 days, and applying by the chelator -physics effect pharmaceuticals containing [0.4 % Cu EDTA + 1.2 % Mg EDTA + 2.4 % Ca EDTA + 70 % + 100 % water], the result is that after 24 hours the infection in treated tissues are significantly decreased/the inflammation in treated tissues are significantly decreased, after 3 days the treated tissues are completely without infection/inflammation, and after 7 days the open wound on the treated tissues are healed and the treated tissues are cured.
  • -Pharmaceuticals to treat the dark-colored benign tumors under the skin (on humans) with a diameter of about 8 mm by applying to the open wound on the tumors (open wounds are created by making needle incisions on the surface of the tumors), and apply about 6 times/day for 10 days, and apply with chelator-strong physics effect pharmaceutical containing [0.4 % Cu EDTA + 1.2 % Mg EDTA + 2.4% Ca EDTA + 0.5% triethylenetetramine diethylenetetraminepentaacetate + 70% glycerol + just enough 100% water], the result is that after 3 days the tumor size is clearly reduced and a solid core in the middle of the treated tumor to appear, after 7 days this core becomes more solid and shrinks, after 19 days this solid core falls out of the tumor treatment, and after 10 days, the open wound heals and the surface of the tumor treated is flat as the flat of the skin surface, and leaves negligible scars.
  • the chelator-physical effect pharmaceutical to treat the melanoma tumor (on humans) with the diameter of about 12 mm, by injecting into the tumor the solution of the chelator -physical effect pharmaceutical] containing [0.4 % Cu EDTA + 1.2 % Mg EDTA + 2.4 % Ca EDTA + 0.5 % triethylenetetramine diethylenetetraminepentaacetate + 70 % glycerol + water just enough 100%], the result is similar to the results of treating dark-colored benign tumors as mentioned in above section.
  • the chelator-foam-physics effect pharmaceutical to treat the fungal-infection tissue (on human) are warts (the tissue proliferating by HPV viruses) with the size of 4 mm to 10 mm, by applying to the surface of these warts the chelator-foam-physics effect pharmaceutical containing [0.4 % Cu EDTA + 1 ,2% Mg EDTA + 2.5% tri ethylenetetramine di ethylenetetraminepentaacetate + 70% glycerol + 10% H2O2 + enough 100% water], apply for 5 days, and apply 4-6 times per day, the result are that after 3 days the hardness dry core to appear in the middle of the treated tissues, after about 6 days this hardness dry core falls out of the treated tissues, and a few days later the surface of the treated tissues become flat as the flat of the skin surface around the treated tissue, and leaves almost no scars.
  • the chelator solution to treat the environmental with the composition containing [1% Ca EDTA + 1% propylene glycol + 100% water] the chelator solution is sprayed into the rooms having persons with Covid 19, can spray into the room space about 5 minutes before the caregivers entered the room and came into contact with the patient with Covid 19 (both were wearing masks, and the drug solution was also sprayed on the caregiver's mask, after 15 days the caregivers were not suffered the Covid 19 disease.
  • the chelator solution to treat the environmental with the composition containing [10% Ca EDTA + water just enough 100% ] the solution is sprayed onto the water surface where fish clusters is floating and already to die in water channels with stagnant water/slow-flowing water, with the fishes are poisoned by toxins (water-soluble toxins) that accumulate on the land during the dry season, the results are that the above water surface areas that are treated as mentioned above, the fishes dived down after about 10 minutes, while in untreated water surface areas, the fish still float and a few hours later several of these floating fishes died.
  • the cream is used to apply to skin areas with acne/melasma (due to the accumulation of heavy metals, such as due to the accumulation of Hg by cosmetics containing Hg, or due to the accumulation of heavy metals naturally due to low concentration of polyamine derivatives in the skin for a long time)/dry skin areas/inelastic skin areas, the results are that after 1 week of applying the above cosmetic cream to the above mentioned skin areas and applying at least once a day, the acne will be significantly reduced/disappeared, and mechanical property of the skin/the moisture of the skin will be significantly improved, after 6 months, the melasma will be significantly reduced/disappeared.
  • the chelator solution to treat the environmental with the composition containing [3% Ca EDTA +water just enough 100%] the solution to treating the water contaminated with heavy metals in canals having fish/in ponds having fish where in the beginning of the rainy season, the water rich in heavy metal derivatives that are poured from the land into these canals/pond, causing fish to float and die, the result are that after 20 minutes after spreading the above the chelator solution evenly on the water surface where the fishes are floating, the fishes dive and the fishes does not die.
  • -Food preservation chelator additive has the composition containing [2% tri ethylenetetramine di ethylenetetraminepentaacetate + water just enough 100%], solution is sprayed on the surface of food/to mix into processed foods (such as pate) to prevent food that are kept for a long time to avoid the appear toxins/neurotoxins due to contamination with microorganisms that produce toxins/neurotoxins, due to triethylenetetramine di ethylenetetraminepentaacetate inactivates toxins/neurotoxins in low concentration (over 30 ppm) while preventing the proliferation of organic mattes-decomposition microorganisms, therefore, when the processed foods in grining form are added with the above additives at concentrations above 30 ppm in processed foods, these additives will prevent the risk from poisoning for the user.
  • the chelator solution to wash the hands/to sanitize the surfaces/to spray into the environment where people live, the chelator solution has the composition containing [2% Ca EDTA + 1% propylene glycol + 70% alcohol + water just enough 100%], after the alcohol and water evaporate from the sterilized surface, the sterilized surfaces are left with [Ca EDTA + propylene glycol] which is strongly permeable to pathogenic microorganisms, and make the pathogenic microorganisms to immediately die right after the alcohol and water to evaporate from the sterilized surfaces with the above chelator solution.
  • the chelator additive to preserve blood which helps prevent blood from clotting and helps the transfused blood has the ability to resist bacteria or has the ability to treat diseases caused by microorganisms or has the ability to strengthen the immune system
  • the chelator additive has the composition containing triethylenetetramine diethylenetetraminepentaacetate, and this additive is added to the blood for transfusion, with the concentration of triethylenetetramine diethylenetetraminepentaacetate in the blood for transfusion is from 100 ppm to 1000 ppm.
  • this chelator solution to preserve the tissue awaiting the transplantation that has the composition containing [2000 ppm tri ethylenetetramine di ethylenetetraminepentaacetate + 30% glycerol + enough 100% water]
  • this chelator solution is used for preservation of living tissues in environments with temperatures from 1 degree Celsius to 4 degrees Celsius waiting for a tissue transplant, the tissue prepared for transplantation is placed cold water at 1 degree Celsius until the glycerol concentration in the tissue drops below 10% before it can be transplanted, living tissue preservation solution made of tri ethylenetetramine diethylenetetraminepentaacetate and glycerol, therefore the biological structure of tissues are less damaged and the physical structure of the tissues are less damaged, so when transplanting theses tissues are less rejected and less infected, after transplantation, it is necessary for the patient to take chelator pharmaceuticals for a long enough time to help to avoid the graft rejection.
  • the chelator solution to use in open surgery that has the composition containing [500 ppm triethylenetetramine triethylenetetraminepentaacetate + 20% glycerol + 5% propylene glycol + sufficient water], the solution is applied to exposed tissues where open surgery is performed, this chelator solution will help prevent the infection for open wounds, and helps wounds after stitching after surgery to heal quickly (experiments of applying the above solution to open wounds under the skin with infection, makes the infection go away quickly and especially reduces pain and makes the treated tissue quickly recover, thanks to the glycerol makes the treated tissue to be wet, and chelator cleans the treated tissue from the accumulation of Zn ions/other transition metal ions which help the treated tissue to recover quickly).

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Des métalloprotéines sur la surface de micro-organismes pathogènes ont une densité élevée d'ions Zn, ces ions Zn aident les micro-organismes pathogènes à se lier à des ions métalliques sur des métalloprotéines sur une surface de cellule hôte (similaire à des ions Zn trouvent et se lient à d'autres ions métalliques dans des batteries électriques avec des paires d'électrodes métalliques Zn-autres). Des micro-organismes pathogènes et leurs fragments libèrent des produits riches en Zn dans le corps hôte, ces produits riches en Zn font rapidement des chélateurs ayant une forte capacité de rétention des ions Zn (qui sont principalement un dérivé d'acides polyamines/aminopolycarboxyliques) totalement contenir des ions Zn, appauvrissent ces chélateurs actifs, lorsque des chélateurs actifs sont appauvris, les produits riches en Zn se lient à des métalloprotéines hôtes, générant la plupart des symptômes, puis le corps hôte fournit de nouveaux chélateurs actifs qui séparent des produits riches en Zn de métalloprotéines hôtes, repoussant la plupart des symptômes. Les médicaments de l'invention contiennent des chélateurs ayant une forte capacité de rétention des ions Zn (qui sont un dérivé d'acides polyamines/aminopolycarboxyliques) qui ont les effets suivants : - réduire rapidement la plupart des symptômes ; - affaiblir les micro-organismes et perd leur capacité à se lier à des cellules hôtes ; - renforcer le système immunitaire hôte ; - éliminer l'accumulation de produits riches en Zn à partir de métalloprotéines hôtes, repousser la plupart des symptômes ; - repousser le syndrome post-maladie ; - etc. Les médicaments de l'invention contiennent [agents chélateurs actifs élevés + agent qui crée de forts effets physiques (dans les tissus traités)] pour traiter des tissus malades (tels que des tissus d'infection bactérienne/tissus nécrotiques/tissus d'infection fongique/tumeurs bénignes/tumeurs cancéreuses) avec une efficacité remarquable.
PCT/IB2024/054083 2023-05-05 2024-04-26 Produits pharmaceutiques contenant des chélateurs ayant une forte capacité de rétention des ions zn pour le traitement de symptômes et de maladies provoqués par des micro-organismes/maladies provoqués par des toxines ou des neurotoxines/cancer/plusieurs syndromes Pending WO2024231774A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2024269697A AU2024269697A1 (en) 2023-05-05 2024-04-26 Pharmaceuticals containing chelators with strong zn ions-holding feature for the treatment of symptoms and diseases caused by microorganisms/diseases caused by toxins or neurotoxins/cancer/several syndromes
IL324359A IL324359A (en) 2023-05-05 2025-10-30 Drugs containing chelators with strong zinc ion retention properties for the treatment of symptoms and diseases caused by microorganisms/diseases caused by toxins or neurotoxins/cancer/a number of syndromes
MX2025013222A MX2025013222A (es) 2023-05-05 2025-11-04 Productos farmaceuticos que contienen quelantes con una fuerte capacidad de retencion de iones de zinc para el tratamiento de sintomas y enfermedades causados por microorganismos, enfermedades causadas por toxinas o neurotoxinas, cancer y varios sindromes.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
VN1202302967 2023-05-05
VN1-2023-02967 2023-05-05

Publications (1)

Publication Number Publication Date
WO2024231774A1 true WO2024231774A1 (fr) 2024-11-14

Family

ID=91129511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/054083 Pending WO2024231774A1 (fr) 2023-05-05 2024-04-26 Produits pharmaceutiques contenant des chélateurs ayant une forte capacité de rétention des ions zn pour le traitement de symptômes et de maladies provoqués par des micro-organismes/maladies provoqués par des toxines ou des neurotoxines/cancer/plusieurs syndromes

Country Status (4)

Country Link
AU (1) AU2024269697A1 (fr)
IL (1) IL324359A (fr)
MX (1) MX2025013222A (fr)
WO (1) WO2024231774A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494935A (en) * 1992-01-17 1996-02-27 University Of Utah Research Foundation Methods for oral decorporation of metals
WO2004110463A1 (fr) * 2003-06-06 2004-12-23 The Procter & Gamble Company Compositions de prevention et de traitement de symptome de type rhume et grippe comprenant du zinc chelate
US20070293466A1 (en) 2004-11-03 2007-12-20 Thompson Robert C Antimicrobial Chelates
US20090030079A1 (en) 2007-07-27 2009-01-29 Aton Pharma, Inc. Uses of trientine and penicillamine as countermeasures to metal contamination
CN107325891A (zh) * 2017-06-16 2017-11-07 中原工学院 一种特效去除重金属的全天然绿色果蔬洗涤盐
US11033579B2 (en) 2015-09-24 2021-06-15 Innolife Co., Ltd. Use of trientine to deliver copper to ischemic tissue
US20220280450A1 (en) * 2021-03-05 2022-09-08 Philera New Zealand Ltd. Prevention and treatment of coronavirus and related respiratory infections

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494935A (en) * 1992-01-17 1996-02-27 University Of Utah Research Foundation Methods for oral decorporation of metals
WO2004110463A1 (fr) * 2003-06-06 2004-12-23 The Procter & Gamble Company Compositions de prevention et de traitement de symptome de type rhume et grippe comprenant du zinc chelate
US20070293466A1 (en) 2004-11-03 2007-12-20 Thompson Robert C Antimicrobial Chelates
US20090030079A1 (en) 2007-07-27 2009-01-29 Aton Pharma, Inc. Uses of trientine and penicillamine as countermeasures to metal contamination
US11033579B2 (en) 2015-09-24 2021-06-15 Innolife Co., Ltd. Use of trientine to deliver copper to ischemic tissue
CN107325891A (zh) * 2017-06-16 2017-11-07 中原工学院 一种特效去除重金属的全天然绿色果蔬洗涤盐
US20220280450A1 (en) * 2021-03-05 2022-09-08 Philera New Zealand Ltd. Prevention and treatment of coronavirus and related respiratory infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUSSELL TALORPAUL CREES, TREATMENT OF TUMOR, 15 May 2004 (2004-05-15)

Also Published As

Publication number Publication date
MX2025013222A (es) 2025-12-01
IL324359A (en) 2025-12-01
AU2024269697A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
ES2791485T3 (es) Método y material para complejación en el sitio activo de moléculas biológicas
DK2155222T3 (en) Extract of Trigonella foenum-graecum
CN109316536A (zh) 一种皮肤黏膜消毒剂及其制备方法
CN102550601A (zh) 一种碘伏消毒液及其制备方法
EP4203920A1 (fr) Nanosolutions d'ozone liposomales
RU2144828C1 (ru) Способ лечения водных животных и композиция, содержащая каепутовое масло
US20070148262A1 (en) Bactericidal and virucidal composition containing natural products
AU2024269697A1 (en) Pharmaceuticals containing chelators with strong zn ions-holding feature for the treatment of symptoms and diseases caused by microorganisms/diseases caused by toxins or neurotoxins/cancer/several syndromes
KR102308571B1 (ko) 산돌배나뭇잎추출물이 함유된 기능성 조성물
KR102251911B1 (ko) 은 이온 항균 손세정제 및 그 제조 방법
KR101934828B1 (ko) 해수와, 본래 해수와 섞이지 않는 적어도 하나의 화합물을 함유하는 수용성 이온 용액
CN102088984A (zh) 幽门螺杆菌驱除剂和驱除方法
CN108186418A (zh) 婴儿卫生湿巾及其生产工艺
CN113368007B (zh) 一种口腔用多功能气雾剂及其制备工艺
US20230240989A1 (en) Liposomal ozone nanosolutions
CN108208034A (zh) 一种杀虫和肥效一体的生物杀虫剂及其制备方法
CN101480428A (zh) 橄叶乐果精华液及其用途
CN106212542A (zh) 一种兽用中药消毒剂的制备方法
CN106359480A (zh) 高效杀虫消毒剂
US10206899B2 (en) Method for removing bacterial biofilms
CN110946995A (zh) 天然草本宠物专用除臭除虫消毒剂
RU2477149C1 (ru) Биоцидный состав для пропитки салфеток
CN104056293B (zh) 一种空气清新剂
KR20100117261A (ko) 샴푸 조성물
CA3085312C (fr) Compositions antibacteriennes comprenant du sel de sulfate alkyleth; un sel de zinc et des agents de surface sulfo-acetates alkyles et/ou sulfosuccinates alkyles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24726729

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 324359

Country of ref document: IL

WWP Wipo information: published in national office

Ref document number: 324359

Country of ref document: IL

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025023593

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: AU2024269697

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 11202507361Q

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202507361Q

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2024269697

Country of ref document: AU

Date of ref document: 20240426

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2024726729

Country of ref document: EP